RxDoctor Payments Data

Pari Nikpey, MD

Neurology · Charlottesville, VANPI 1689629446

Payments from drug & device makers

$22,425in general payments, 2019–2025

Across 248 payments — averaging $90.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$14K
  • Biohaven Pharmaceuticals, Inc.$4K
  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • Supernus Pharmaceuticals, Inc.$374
  • Lundbeck LLC$343
  • Pfizer$214
  • plus $901 from 13 others

What the payments were for

  • Speaking & faculty fees$17,08176%
  • Travel & lodging$1,2636%
  • Food & beverage$3,99418%
  • Education$860%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,425 in reported general payments places this provider in the 75th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$130,096
Medicare patients
66
Services billed
16,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate34$66,035
Emgality PenGalcanezumab-Gnlm35$38,849
BotoxOnabotulinumtoxina21$29,151
QuliptaAtogepant12$16,840
UbrelvyUbrogepant11$12,221
Propranolol Hcl21$1,202
Sumatriptan Succinate60$810
Amitriptyline Hcl42$461
Topiramate31$387
Pregabalin14$141
Promethazine Hcl13$36
Cyclobenzaprine Hcl12$5

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$214$66,03534 claims
AbbVieBotox, Qulipta, Ubrelvy$14,119$58,21244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 474 neurology providers in Virginia.

Other neurology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →